Tocotrienols for School-going Children With ADHD

NCT ID: NCT01855984

Last Updated: 2013-06-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if tocotrienol supplementation given to school going children with ADHD will result in reduction of their ADHD symptoms.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective of the study is to:

a. Determine if supplementation of tocotrienol compared to placebo has an effect on the symptoms of school going children with ADHD.

The secondary objective is to:

1. Determine if supplementation of tocotrienol compared to placebo has an effect on the dose of current medication used in school going children with ADHD.
2. Determine the safety of tocotrienol in the study population.
3. Determine if tocotrienol levels in children with ADHD correlate with their symptom scores.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Attention Deficit Disorder With Hyperactivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral mixed tocotrienols

2 capsules containing 100mg mixed tocotrienols per capsule taken orally once a day for 6 months

Group Type EXPERIMENTAL

Oral mixed tocotrienols

Intervention Type DIETARY_SUPPLEMENT

200mg per day

Placebo

2 capsules containing soya bean oil taken orally once a day for 6 months

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral mixed tocotrienols

200mg per day

Intervention Type DIETARY_SUPPLEMENT

Placebo

Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tocovid Suprabio.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with ADHD in accordance with the Diagnostic and Statistical Manual (DSM) IV criteria.
* Be able to swallow soft gel capsules.
* If already on medication for ADHD, the dose of the medication must be stable for the last 3months
* Be able to attend all follow up visits.
* Be agreeable to have their teacher score the National Initiative for Children's Healthcare Quality (NICHQ) Vanderbilt Assessment Scale - Teacher Informant
* Be willing to have their blood taken 3 times during the study.

Exclusion Criteria

* ADHD caused by syndromes, inborn errors of metabolism, or structural brain lesions.
* Co-existing chronic liver disease
* Current use of anticoagulant or antiplatelet drugs.
Minimum Eligible Age

6 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Penang Hospital, Malaysia

OTHER_GOV

Sponsor Role collaborator

RCSI & UCD Malaysia Campus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

May Loong Tan

Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

May Loong Tan, MRCPCH(UK)

Role: PRINCIPAL_INVESTIGATOR

RCSI & UCD Malaysia Campus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Child & Adolescent Psychiatry Unit, Hospital Pulau Pinang

George Town, Pulau Pinang, Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NMRR-6767

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.